Objectives. To establish whether the decision to stop, continue or switch TNF inhibitor (TNFi) therapy to a biologic drug with an alternative mode of action following a serious infection (SI) impacts upon the risk of recurrent SI in patients with RA.
Introduction
Biologic drugs have revolutionized RA management, but the risk of serious infection (SI) associated with the disease and its therapies is concerning for clinicians and patients [1] . SI is a frequent cause of drug cessation [2] . The British Society for Rheumatology Biologics Register-RA (BSRBR-RA) reported a small but statistic-ally significant increased risk of SI associated with TNF inhibitor (TNFi) therapy compared with non-biologic therapy [TNFi SI rate 4.2/100 patient-years follow-up (95% CI: 4.0, 4.4) vs non-biologic therapy 3.2/100 patient-years of follow-up (95% CI: 2.8, 3.6)] [3] . Similar findings have been reported from other national biologic registries [46] . A prior history of SI is a predictor of recurrent SI in RA [7, 8] .
British Society for Rheumatology guidelines advise caution in using TNFi in patients at high risk of infection [9] . Discontinuing TNFi during a SI is recommended, restarting only when infection has completely resolved [9] . The decision to stop, continue or switch to an alternative biologic drug class after SI remains at the discretion of the prescriber in collaboration with the patient.
This study investigated the pattern of and association with biologic prescribing choices (i.e. drug cessation, continuation or switch to a drug with an alternative mode of action) following a SI and future SI risk.
Methods
The BSRBR-RA is a large prospective observational cohort established to evaluate the safety and efficacy of biologic drugs (including adalimumab, etanercept, infliximab, certolizumab pegol, anakinra, rituximab and tocilizumab) [10] . Abatacept is not included in the BSRBR-RA. The study achieved ethics approval from the Multicentre Research Ethics Committee for North West England in December 2000 (MREC00/8/053, Integrated Research Application System 64202). All participants give written informed consent. The register's methodology has been previously described [10] .
Baseline assessment
Data captured at baseline (defined as the date of the first registered drug with the BSRBR-RA) included patient demographics, disease duration, DAS in 28 joints (DAS28), HAQ score, smoking status, oral steroid use and comorbidity. Current and previous drug exposures were also recorded.
Patient follow-up
Questionnaires were sent to supervising rheumatologists and patients biannually for 3 years (annually to rheumatologists thereafter) to gather information on drug exposures and adverse events. The BSRBR-RA was notified of any deaths of recruited patients by NHS Digital.
Case definition
Participants were included if they suffered at least one SI episode while on their first TNFi (or within five half-lives of stopping TNFi) and survived at least 60 days after the index SI. SI events after 1 June 2008 were considered. This date was when the first patients in the BSRBR-RA rituximab cohort were recruited (thus allowing a drug switch to an alternative biologic class from TNFi). The data cut-off date was 30 June 2016.
SIs were defined as episodes requiring intravenous antibiotics, hospitalization or resulting in death. Cases of SI were identified through all three methods of patient followup. Patient reported SIs required verification by their treating rheumatologist. Only SIs occurring with first biologic drug exposures on TNFi were included. SIs were coded using the Medical Dictionary for Regulatory Activities terminology and classified into seven categories (sepsis, lower respiratory, musculoskeletal, skin and soft tissue, gastrointestinal, genitourinary, and other; see supplementary Table S1 , available at Rheumatology online).
Patient follow-up began 60 days after the index SI. This ensured only new episodes of SI were considered and allowed adequate time for SI resolution. The biologic drug decision following an index SI was based upon an intention to treat analysis. If a patient was recorded as receiving TNFi at day 60 post-index SI date, he or she was considered as having continued biologic. If a patient was recorded as receiving either rituximab or tocilizumab 60 days after an index SI, he or she was considered to have switched drug. Follow-up continued for 12 months, ending in the event of patient death, recurrent SI or reaching the end of follow-up. Individual patient record review was performed to manually code treatment decisions. A decision tree is shown in supplementary Fig. S1 , available at Rheumatology online. This analysis did not consider what happened to biologic exposure in the immediate period around the infection episode.
Statistical methods
Characteristics of biologic-treated patients with SI during follow-up were tabulated. Incidence rates were calculated, and a multivariable Cox proportional hazards model was used to identify whether biologic treatment decisions were associated with future SI risk. Adjustments were made for age, gender, baseline DAS28, HAQ, disease duration and polypharmacy (a surrogate measure of comorbidity). Polypharmacy has been associated with an increased risk of unplanned hospitalizations and was used as a surrogate measure for comorbidity [11] . Individuals were divided into three categories (05, 610, 511) based on the number of medications they were taking (excluding RA therapies). Multiple imputation of missing baseline covariates was performed with 20 cycles using the ICE package in Stata 14 (StataCorp LLC, College Station, TX, USA).
Results
In total, 21 943 patients with 115 423 patient-years followup were registered in the BSRBR-RA; 1583 patients suffered at least one SI while receiving their first TNFi during the follow-up period. The 30-day mortality following SI was 10.4% (95% CI: 9.2, 11.6%). The baseline demographics are presented in Table 1 . Lower respiratory tract infections were the most frequently observed SI (42% of all events), followed by skin (19.5%), gastrointestinal (10.6%) and genitourinary infections (10.1%). Sixty days after an index SI, most patients (72.5%) were recorded as continuing TNFi, 21.3% had stopped drug and 6.2% had switched to an alternative drug class (rituximab or tocilizumab). Comparing baseline characteristics, patients who switched drug class were younger, more likely to be male, smokers, steroid users, had higher DAS28 and lower HAQ compared with patients who continued or stopped TNFi following SI. Irrespective of the index SI organ class, most patients had continued TNFi 60 days post-index SI. The highest percentage of patients still 'off drug' at 60 days (31%) were those who suffered musculoskeletal infections; however, most patients (69%) had restarted biologic therapy.
During the 12-month follow-up period, there were 223 recurrent SI events. The rate of recurrent SI in the whole cohort was 25.6% per annum (95% CI: 22.5, 29.2%). The rate of recurrent SI was highest in patients who at day 60 were still off their TNFi: 42.6% per annum (95% CI: 32.5, 55.7%). Among this cohort, 8% had restarted a biologic prior to having a second event whilst 92% had not received any further biologic therapy prior to their recurrent infection. The rate of recurrent SI was 23.2% per annum (95% CI: 19.9, 26.9%) in patients who continued TNFi following SI and lowest in patients who switched TNFi to a biologic with an alternative mode of action (12.1% per annum, 95% CI: 3.9, 37.4%).
In an adjusted multivariate Cox model, compared with patients stopping biologic therapy, patients who continued or switched drug class had a significantly lower risk of recurrent SI [drug continuation hazard ratio (HR) = 0.54, 95% CI: 0.40, 0.74; drug switch HR = 0.29, 95% CI: 0.09, 0.95]. Other predictors of recurrent SI included female gender, increasing age and baseline steroid use ( Table 2) .
Discussion
Sixty days after an index SI, most patients were recorded as continuing TNFi. The recurrent SI rate was lower in patients who continued TNFi or switched drug class following a SI compared with patients who had not restarted TNFi at 60 days. Either there is a clinical advantage of continuing biologic immunosuppression following a SI or this reflects a channelling bias.
Higher DAS28 is an independent predictor of SI [12] . Earlier re-introduction of biologic therapies may have provided better disease control and thereby lowered the risk of recurrent SI. In those who stopped their biologic following SI, there may have been higher corticosteroid exposure to manage their RA. This strategy may convey a higher infection risk than biologic treatment. Alternatively, patients at the highest SI risk could have been channelled away from continuing biologic therapy.
The risk of suffering a recurrent SI was lowest in patients who switched biologic therapy class to either tocilizumab or rituximab. This group were younger, with higher DAS28, lower HAQ and lesser polypharmacy burden compared with the other groups. These patients may represent the 'fittest' in the cohort with a lower baseline SI risk and hence the significantly lower hazard of suffering a recurrent SI. Caution should be exercised in interpreting this result as the number of patients who switched biologic was low and the HR 95% CI was wide. Infection incidence rates are similar across biologic drug classes [13, 14] . A recent study comparing the risk of SI in patients who had failed a TNFi and switched to either rituximab or a second TNFi found no significant difference in SI risk between drugs [15] . It is difficult to explain the lower risk of SI in biologic switch patients by the different infection risk profiles of rituximab or tocilizumab. The traditional predictors of SI (disease duration, smoking, seropositivity, DAS28, HAQ) were not significantly associated with an increased risk of recurrent SI in the adjusted Cox model. The lack of association is likely to be spurious and may be explained by selection bias.
There are limited data in the literature regarding biologic prescribing decisions following SI and the risk of recurrent SI. Using American Medicare data, Yun et al. [16] reported similar proportions of patients continuing, stopping and switching biologic therapies following SI. Compared with our results, a higher rate of recurrent SI (34.6/100 patient-years) was reported in patients continuing TNFi following SI. This is likely explained by an older, more steroid dependent cohort and by differences in study methodology. Accortt et al. [17] considered the incidence of recurrent SI in patients treated with a TNF inhibitor, other biologic or non-biologic anti-rheumatic drug across a variety of inflammatory rheumatological indications. Patients treated with a TNFi in combination with a non-biologic DMARD had a lower risk of recurrent SI compared with patients treated with a non-biologic DMARD alone. This may be explained by either better disease activity control, supporting our results, or channelling bias.
A strength of the BSRBR-RA is robust coding of adverse events and prospective data capture. However, the 6-monthly data capture schedule may have affected the accuracy of infections recorded, timing and the treatment decisions made. We manually reviewed the dataset and validated the patients in whom the subsequent biologic treatment decision post-SI was not apparent to maximize data accuracy.
Although we adjusted for steroid exposure at baseline, the BSRBR-RA lacks detailed longitudinal data regarding steroid use. It was not possible to determine whether the steroid exposure, and particularly the dose, was higher in subjects who stopped biologic after SI compared with those who continued or switched therapy. Similarly, we accept that DAS28 and HAQ score at the time of infection was not adjusted for. This relates to the schedule of data capture.
It is likely that the fittest patients who were at the lowest baseline risk of experiencing recurrent SI were preferentially channelled to restart biologic post-SI. Frailer patients may have been channelled towards stopping biologic drug due to the risk of recurrent SI associated with restarting biologic being too high.
It was not possible to adjust for the heterogeneity or severity of SI. It is plausible that the patients who suffered the most SIs remained off drug. Using length of hospital stay as a surrogate marker for SI severity was not a robust method as there are many confounding factors that could increase length of hospitalization aside from infection. By using polypharmacy as a comorbidity surrogate, we avoided the need to use multiple categorical variables in the regression models. Sensitivity analyses adjusting for comorbidities individually made no meaningful difference to our results.
Patients selected to continue or switch immunosuppression after their index SI had a lower recurrent SI rate compared with those who stopped immunosuppression. We advise exercising caution when interpreting our results. It would be wrong to assume a directly causal explanation as channelling bias is inevitable. We acknowledge unmeasured confounders for which we cannot adjust. We are unable to answer merits of choosing to switch or continue biologic class after SI. The risks and benefits of restarting immunosuppression following a SI need to be carefully considered on an individual patient basis.
